Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)Retained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming (PHAR) Convertible Debt (2020 - 2025)

Historic Convertible Debt for Pharming (PHAR) over the last 6 years, with Q3 2025 value amounting to $93.1 million.

  • Pharming's Convertible Debt rose 112.81% to $93.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.1 million, marking a year-over-year increase of 112.81%. This contributed to the annual value of $78.2 million for FY2024, which is 4278.54% down from last year.
  • Pharming's Convertible Debt amounted to $93.1 million in Q3 2025, which was up 112.81% from $91.3 million recorded in Q2 2025.
  • Pharming's 5-year Convertible Debt high stood at $145.4 million for Q2 2021, and its period low was $120005.0 during Q3 2022.
  • Over the past 5 years, Pharming's median Convertible Debt value was $128.2 million (recorded in 2022), while the average stood at $98.8 million.
  • Its Convertible Debt has fluctuated over the past 5 years, first crashed by 9991.49% in 2022, then surged by 10800632.89% in 2023.
  • Over the past 5 years, Pharming's Convertible Debt (Quarter) stood at $140303.5 in 2021, then soared by 93709.5% to $131.6 million in 2022, then increased by 3.78% to $136.6 million in 2023, then plummeted by 42.79% to $78.2 million in 2024, then rose by 19.17% to $93.1 million in 2025.
  • Its last three reported values are $93.1 million in Q3 2025, $91.3 million for Q2 2025, and $83.8 million during Q1 2025.